With health policy top of the political agenda, now’s the time to supercharge Australia’s biotech sector says new MRCF Board member
Erica Kneipp tapped for $700m biotech fund
Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals
Nasal spray which could fight Covid and other respiratory infections gets funding
New investments for drug research
Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
OncoRes Medical wins IGNITE Madness 2020
Eyeing pandemic’s silver lining for drug trials
Azura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
Nasal spray cuts COVID-19 growth, study shows
Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions
GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)
OncoRes Medical awarded prestigious research funding
Innovative type two diabetes treatment scores $29m
$29M investment to develop new treatment for type 2 diabetes
Vaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)
Nation faces ‘generational loss’ of biotechs warning
Urgent COVID-19 response package needed to support and protect $170b life sciences sector
Bill Ferris, pioneer venture capitalist, appointed Chair of the MRCF
Vaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin
Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination
Multi-million-dollar mission to tackle major global health challenges
